PrecisionLife has entered a multi-target discovery and validation partnership with Ono Pharmaceutical in the field of central nervous system (CNS) disorders. 

According to the research and development (R&D) deal, the combinatorial analytics platform of PrecisionLife will be applied to patient datasets to detect several novel therapeutic targets, which will be developed by Ono. 

Additionally, the drug discovery capabilities of PrecisionLife will be used to offer a clear rationale to Ono for choosing targets. 

These targets will be selected with genetic validation and mechanistic hypotheses, preclinical validation and subject stratification biomarkers to streamline the assets’ clinical development. 

Based on the recommendations of PrecisionLife, Ono will choose targets and obtain global development and commercialisation rights for a pharmaceutical product that works on the target.

PrecisionLife CEO Dr Steve Gardner said: “We are excited to work with Ono on this precision neuroscience collaboration as it brings together our novel insights into complex disease biology with Ono’s extensive drug development expertise.

“We expect this to bring forward effective new treatment options addressing the currently unmet medical needs of key patient subgroups in some of the most challenging common CNS diseases.”

This alliance represents PrecisionLife’s precision medicine and drug discovery expertise in complex chronic ailments with high unmet medical needs. 

Having evaluated more than 40 high-value disease indications, the company has a portfolio of insights and patented discoveries in the DiseaseBank repository.

Ono Pharmaceutical Discovery & Research senior executive officer/executive director Toichi Takino said: “We appreciate PrecisionLife’s unique combinatorial analytics platform for discovering new therapies that meet specific medical needs in complex central nervous system diseases. 

“We expect to increase the efficiency of finding new drug candidates that bring much-needed new therapeutic options to patients through this new collaboration.”